Combination of rituximab and low-dose glucocorticoids for idiopathic refractory nephrotic syndrome with MCD/FSGS: a single-center prospective cohort study.

ABSTRACT:

Background

The treatment of idiopathic refractory nephrotic syndrome (IRNS) remains a difficult problem in clinical practice. This study aims to determine the efficacy and safety of combining low-dose glucocorticoids with rituximab in IRNS treatment.

Methods

This prospective, single-center cohort study enrolled 60 patients who were diagnosed with refractory IRNS with minimal change disease (MCD) or focal segmental glomerulosclerosis (FSGS) and treated at First Affiliated Hospital of Sun Yat-sen University. All patients received a treatment regimen consisting of rituximab (375 mg/m²/week × 4) and low-dose glucocorticoids.

Results

46 complete remissions and 4 partial remissions were observed within 6 months of treatment. Within 12 months of treatment, 48 pati

SUBMITTER: Yimamuyushan A 

PROVIDER: S-EPMC11571727 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature